Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

PPG Industries, Inc. to increase the offer price to EUR 34.00 per share and amend certain other terms of the offer; PPG and Tikkurila Oyj have agreed on an amendment to the combination agreement

PPG Industries, Inc. to increase the offer price to EUR 34.00 per share and amend certain other terms of the offer; PPG and Tikkurila Oyj have agreed on an amendment to the combination agreement TIKKURILA OYJTender OfferFebruary 4, 2021 at 9.35 a.m. EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. Highlights of the Improved Tender Offer by PPG Industries, Inc. ·

Medius strengthens its European partner programme with INTM Group

STOCKHOLM, February 3rd 2021 Medius, a leading provider of spend management solutions has renewed its partnership with consulting and digital services specialists INTM Group.The agreement allows INTM Group to sell, distribute and implement Medius’ simple-to-use, cloud-based and cost effective spend management solutions to its portfolio of customers in France and Belgium.  Cyrille Salvetti, Deputy Director General at INTM group said: “I’m delighted to have expanded our relationship with Medius. For us, we’re always striving to deliver the best quality service and solutions to our

Year-end report 2020

Fourth quarter 2020: ·  Net sales amounted to SEK 3,450m (3,445). · Organic growth was 5% (-2).  · Operating profit excl. items affecting comparability increased toSEK 295m (214), corresponding to an operating margin of 8.6% (6.2). · Items affecting comparability amounted to SEK -144m, primarily related towrite-down of assets following the decision to invest in a new factory in Sweden. · Changes in exchange rates negatively impacted operating profit by SEK -15m. · Profit after tax excl. items affecting comparability amounted to SEK 218m (150),corresponding to

Rejlers to ensure smart solutions at Stortorvet 7 in Oslo

Rejlers has been chosen as an advisor for SMART-technology on the revitalisation and development of Stortorvet 7. Located in the heart of Oslo, this magnificent 32,000 sqm building that faces out onto Stortorvet will house shops, dining options and offices.Rejlers will help ensure that the building becomes both climate-friendly, efficient and user-friendly for tenants and visitors. Owned by Schage Eiendom, the building will be BREEAM certified ”Very Good”, with a focus on sustainability in both its planning and design.   “Stortorvet 7 will have many different functions and will house

Mentice publishes the company’s year-end report for the period January–December 2020

Strong order intake and substantial improvement of the company’s order book as well as operating cash flow  Fourth quarter (October–December 2020) · Order intake amounted to 73.1 (54.7) MSEK. · Net sales amounted to 45.9 (60.2) MSEK. · Operating income for the period before depreciations (EBITDA) totalled 4.3 (11.8) MSEK. · Net income for the period amounted to 3.3 (7.8) MSEK. · Earnings per share (EPS) was 0.14 (0.32) SEK. · Cash flow from operating activities totalled 20.1 (-16.6) MSEK.  Full year (January–December 2020) · Order intake amounted to 168.6

IndiTreat® selected to prestigious multinational ovarian cancer project.

2cureX is pleased to announce that the DECIDER project that aims to develop novel diagnostic tools and effective drug combinations to treat ovarian cancer patients has been awarded a prestigious grant from the EU.2cureX will provide functional precision testing within a prestigious multinational Ovarian Cancer project, DECIDER, which has been granted 15 MEUR from the EU. The invitation to participate is an endorsement of IndiTreat®, and in line with 2cureX’s belief that every cancer patient should be treated individually. In Europe, over 40.000 women die of ovarian cancer every year. In

First Patient Dosed in NefIgArd Open Label Extension Study

Calliditas Therapeutics AB (publ) (”Calliditas”) today announced that the first patient has been dosed in the global open-label extension (OLE) of the Phase 3 NefIgArd study. OLE offers a 9-month treatment with Nefecon to all qualifying patients who have completed the NefIgArd study and will evaluate the efficacy and safety of Nefecon treatment in patients with IgA Nephropathy (IgAN).This study will evaluate patients who have completed the Phase 3 study NefIgArd, which achieved both its primary and key secondary endpoints in the Part A topline data read out on November 8, 2020. All patients

Vestas wins 30 MW order in Poland

News release from Vestas Northern and Central EuropeHamburg, 4 February 2021Vestas has secured a contract to supply, install and commission 15 V110-2.0 MW wind turbines for a 30 MW project in Poland. The order includes a 10-year Active Output Management 5000 (AOM 5000) service agreement as well as a VestasOnline® Business SCADA solution, lowering turbine downtime and thus optimising the energy output. Deliveries and commissioning are expected to begin in the first quarter of 2022. Customer and project names are undisclosed at the customer's request.For more information,

TELESTE: FINANCIAL STATEMENT RELEASE 2020 WILL BE PUBLISHED ON 11 FEBRUARY - INVITATION TO PRESS BRIEFING

Teleste will publish its Financial Statement 1 January – 31 December 2020 as a stock exchange release on 11 February 2021 approx. at 08:30 a.m. EET. A briefing for analysts, media, financial institutions and professional investors will be held virtually in Teams the same day at 09:30 a.m. EET hosted by CEO, Mr. Jukka Rinnevaara and CFO, Mr. Juha Hyytiäinen. PRESS BRIEFING (held in Finnish): Date: Thursday, 11 February, 2021 Time: 09:30-10:30 a.m. EET Location: Microsoft Teams meeting, link will be sent after registration Advance registration requested by noon on 10

Improving service of Sheffield trams with new training solutions

In a new project for public transport operator Stagecoach in the UK, Semcon will develop training to assist the servicing of the new Citylink trams for the Supertram network in South Yorkshire. Quicker and more effective maintenance means more reliable trams and greater availability for passengers. This is in line with Semcon’s aim to grow its business within product information solutions for the rail industry.In this new project Semcon will develop a training set up for service technicians to learn the CAN Bus system used on the Citylink trams. A Controller Area Network (CAN bus) is a

Interim Report Q3 1 April - 31 December 2020

Third quarter (1 October - 31 December 2020) · Net sales increased by 1 percent and amounted to SEK 2,881 million (2,846). · Operating profit before amortisation of intangible non-current assets (EBITA) increased by 28 percent and amounted to SEK 304 million (236) corresponding to an EBITA margin of 10.6 percent (8.3). · Operating profit increased by 27 percent and amounted to SEK 238 million (188) corresponding to an operating margin of 8.3 percent (6.6). · Profit after tax increased by 22 percent and amounted to SEK 174 million (142) and earnings per share before dilution

Rottneros updates its long-term targets

Rottneros’ vision to “Always make a difference" is further enhanced by adding environmental targets to the previously communicated sustainability targets. From 2021 emissions to water (COD) and fossil-free production (CO2) will be added as long-term targets, with the ambition to continuously reduce our environmental impact.Rottneros is part of the circular economy and contributes with wood-based, renewable and recyclable products. Emissions of fossil carbon dioxide from the pulp mills in Vallvik and Rottneros come mainly from fossil fuels and the purchase of electricity. In line with this,

Axactor SE - Acceptances received under mandatory offer

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Reference is made to the mandatory offer dated 29 January 2021 (the "Mandatory Offer") to acquire all shares in Axactor SE (the "Company") at an offer price of NOK 8.00 per share, made by Geveran Trading Co. Limited, a company indirectly controlled by trusts established by Mr. John Fredriksen for the benefit of his immediate family ("Geveran").  On 3 February 2021,

Danske Hypotek AB: Year-end report 2020

Year in briefJanuary – December 2020 (the comparison in brackets refers to 2019) · Operating profit was SEK 1 012 million (965 million) · Net interest income amounted to SEK 1 191 million (1 050 million) · Costs comprised SEK 135 million (101 million) · No credit losses during the period, reversals amounted to net SEK 27 million (SEK +48 million) · Return on equity was 14.5 % (16.9 %) · The CET1 capital ratio was 17.5 % (16.7 %) · Danske Hypotek’s covered bonds have the highest credit rating (AAA) from Standard & Poor’s and from Nordic Credit Rating.Read the full

Operations update

EnQuest PLC, 4 February 2021 Operations update 2020 performance in line with guidance; strong cash generation Expect 2021 production to be between 46,000 Boepd and 52,000 Boepd   Signed an agreement with Suncor Energy UK Limited to acquire its entire 26.69% non-operated interest in the producing Golden Eagle area for an initial consideration of $325 million (see separate announcement issued) §  Upon completion, provides immediate incremental production of c.10 kboepd, c.18 MMboe[1] of 2P reserves and c.5 MMboe[1] of 2C resources §  Provides significant value enhancement

Avidly repeats award win as HubSpot's Global Partner of the Year

Avidly has consecutively won the prestigious award of Global Partner of the Year in the HubSpot 2020 Impact Awards .- We're thrilled and proud to repeat this honor two years in a row. This is a fantastic achievement for Avidly, and well-deserved recognition for the exemplary work everyone at our company commits to together with our customers, says Avidly CEO Jesse Maula. According to Maula, the received award measures not only continuous customer growth but also the technical proficiency and quality of services: - Competition within this field is

Forxiga approved in China for heart failure

4 February 2021 07:00 GMT Forxiga approved in China for heart failure Forxiga is the first SGLT2 inhibitor approved in China for heart failure withreduced ejection fraction in adult patients with and without type-2 diabetes AstraZeneca's Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF). Heart failure (HF) is a life-threatening chronic disease that prevents the heart from pumping sufficient levels of

Year-end report 2020 Bactiguard Holding AB

Recovery in the fourth quarter – Infection prevention key in future healthcareFourth quarter (October-December 2020) · Revenues amounted to SEK 55.6 (59.8) million, a decrease by 7% (adjusted for currency -2%). · EBITDA amounted to SEK 4.9 (12.2) million with an EBITDA-margin of 9% (20%). · Operating profit amounted to SEK -6.4 (1.7) million. · Net profit/loss amounted to SEK -9.4 (1.6) million. Earnings per share amounted to SEK -0.28 (0.05) per share. · Cash flow from operating activities amounted to SEK 3.9 (36.9) million or SEK 0.12 (1.11) per share. Full year (

Strong ending to 2020 results in full year net sales growth of 63% and 27% adjusted EBITA margin

4 February 2021   Following issuance and subsequent listing of the SEK 1.1 billion senior secured bond to finance the acquisition of Poster Store AB (“Poster Store”), the Board of Desenio Group AB (publ) (the “Company” or “Desenio”) hereby publishes the following trading update ahead of the publication of the Company’s year-end report 2020 (which will be published on or around 12 February 2021). As a result of Desenio Group AB’s recent acquisition of Poster Store, the trading update includes certain consolidated pro forma financial figures including Poster Store.Selected preliminary

Kiilto strengthens its position as a comprehensive kitchen hygiene partner by acquiring Svenska Diskbolaget AB

KiiltoClean AB has acquired Svenska Diskbolaget AB, its long-time supplier of solid dishwashing solutions. As a result, Kiilto strengthens its position as a comprehensive food services partner in the Nordics.”We’re truly excited to welcome Diskbolaget team to Kiilto. We believe that together with their know-how, we’re able to further develop the solid dishwashing solution and our whole food services business,” says Juha Suoniemi, Kiilto’s Business Area Director of Professional Hygiene.  The acquisition enables Kiilto to serve its existing and new food services customers with even better

News conference on Kojamo’s Financial Statements Release 2020 on 18 February 2021

Kojamo Plc Press Release, 4 February 2021 at 9:00 a.m. EETNews conference on Kojamo’s Financial Statements Release 2020 on 18 February 2021 Kojamo plc’s Financial Statements Release 2020 will be published on Thursday, 18 February 2021 at approximately 8:00 a.m. EET. Kojamo will publish Financial Statements and the Report of the Board of Directors as well as Corporate Governance Statement and Remuneration Report 2020 on the same day. News conference webcast Kojamo will hold a news conference for institutional investors, analysts and media on 18 February 2021 at 10:00 a.m. EET as a

Interim Report for the period January – December 2020

New data provides further support for BAN2401 (lecanemab)Key events during the fourth quarter 2020 · BioArctic’s drug candidate BAN2401 was assigned an international nonproprietary name (INN): lecanemab. · Further data for drug candidate lecanemab (BAN2401) from the Phase 2b open-label extension study were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. Impact of COVID-19 on the company has been limited · The spread and negative effects of the coronavirus during the year had a serious impact on society, the economy and the lives of private

Year-end report 2020

The fourth quarter marked a period of strong organic revenue growth for Accessibility, which together with the successful implementation of the Lift Up Program contributed to an improved adjusted EBITA margin.Fourth quarter 2020 · Revenue amounted to MEUR 59.2 (61.9). · Organic growth was 5.6%. · The gross margin was 43.8% (39.4). · Adjusted EBITA amounted to MEUR 7.9 (3.7), corresponding to a margin of 13.3% (6.0). · EBIT totaled MEUR 6.1 (-8.2). · Net profit for the period (including discontinued operations) amounted to MEUR 2.0 (-11.5). · Earnings per share (

There are no items matching the current filter
There are no more items matching the current filter
Back to top